Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
colorectal neoplasms/tyrosine
Veza se sprema u međuspremnik
Stranica 1 iz 55 rezultatima
Tyrosine Kinase Inhibitor (TKI) + Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
At present, the later-line treatment of metastatic colorectal cancer (mCRC) can bring benefits to subjects. However, the overall efficacy of treatment is still low. The programmed cell death protein 1 (PD-1) blockade alone in MSS/pMMR mCRC is inefficiency, highlighting a need for strategies that
Value of CD26 Positive Leukemic Stem Cell in Myeloproliferative Neoplasm
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Classic Myeloproliferative neoplasms (MPNs) are a heterogeneous group of diseases including Chronic myeloid leukemia (CML), polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) (Levine et al., 2007).
According to WHO 2016 classification which also included chronic
Anlotinib Plus Sintilimab as First-line Treatment for Patients With Advanced Colorectal Cancer (APICAL-CR)
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Anlotinib is a new, orally administered tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptors (PDGFR), and c-kit. Sintilimab is a fully human IgG4 monoclonal antibody that binds
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Section 1:title and overview Title: Relationship between histopathological features, mutation status, 18F-FDG PET/CT radiomic imaging parameters as well as clinical outcome in patients with treatment-naïve non-small cell lung cancer(NSCLC).
Overview: Nowadays, the most increasingly rapid incidence
Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Biliary tract cancer arises from the epithelial cells of the bile ducts. Until nowadays, no standard second-line treatment has been established following recurrence from the first-line treatment. Angiogenesis plays a key role in the carcinogenesis and development of biliary tract adenocarcinoma.
Zinc Supplement in Regorafenib Treated mCRC Patient
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
This study is aimed to investigate the effect of zinc supplementation on improving regorafenib treatment safety and efficacy in patients with metastatic colorectal cancer (mCRC). The difference in grade 2 or worse hand-foot skin reaction (HFSR) incidence within the first 8 weeks of regorafenib
Clinical Trial to Evaluate Pharmacokinetics,Safety and Immunogenicity of Single Injection of CDP1 to Healthy Volunteers Compared to Erbitux
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVES:
Primary:
To compare the pharmacokinetic characteristics of a single dose between CDP1 and the original drug Erbitux in healthy volunteers.
Secondary :
To compare the safety and immunogenic characteristics of the single dose between CDP1 and the original drug Erbitux in healthy
Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The goal of this study is to evaluate the changes in genomic and immune biomarkers in tumor, peripheral blood and stool samples, in addition to changes in radiomic profiles, of subjects with advanced Mismatch Repair Proficient Coloretal Cancer (MMRp-CRC), Pancreatic Adenocarcinoma (PA), or
Biomarkers for Apatinib and Bevacizumab in Second-line Therapy for Colorectal Cancer(BABST-C)
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Based on inclusion and exclusion criteria, eligible mCRC patients are enrolled. the chest-abdonimal-pelvic CT with brain MRI and blood tests are examined to assess base-line measurable lesions and guarantee adequate organ function prior to enrollment. The written consents are signed before
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
A Preliminary Clinical Study on the Pharmacokinetics and Safety of CDP1 in Patients With Advanced CRC or HNSCC
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
OBJECTIVES:
Primary:
To compare the pharmacokinetic characteristics of a single dose between CDP1 and the original drug Erbitux In patients with advanced metastatic colorectal cancer.
Secondary :
1. To compare the safety and immunogenic characteristics of the single dose between CDP1 and the
Satisfaction and Quality of Life Comparison Between Patients Using Cicaplast Baume B5 Versus Dexeryl for the Management of Cutaneous Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors (iEGFR)
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
The arrival of new therapeutic strategies such as targeted therapies has led to real progress in the treatment of cancers. Tyrosine kinase inhibitors and antibodies to epidermal growth factor receptors (EGFR), or iEGFR, target one of the major pathways of tumor cell proliferation. These treatments
Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Standard second line chemotherapy includes chemotherapy based on irinotecan or chemotherapy based on oxaliplatin.
Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular endothelial growth factor receptor 2 (VEGFR-2), with a
Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Colorectal cancer is a common clinical gastrointestinal cancer. In addition to the early diagnosis of some patients, approximately 50% of patients have had distant metastases at the time of diagnosis. For patients with advanced colorectal cancer, systemic chemotherapy is the main treatment. We
A Study of Apatinib Treatment in for Advanced Ovarian Cancer
Samo registrirani korisnici mogu prevoditi članke
Prijava Registriraj se
Ovarian cancer and fallopian tube cancer are common gynecological malignancies in our country. Ovarian cancer ranks the second in the incidence of gynecologic malignancies. The mortality rate is the highest. The following three major characteristics exist: First, 70% of the patients are advanced
Najkompletnija baza ljekovitog bilja potpomognuta znanošću
- Radi na 55 jezika
- Biljni lijekovi potpomognuti znanošću
- Prepoznavanje bilja slikom
- Interaktivna GPS karta - označite bilje na mjestu (uskoro)
- Pročitajte znanstvene publikacije povezane s vašom pretragom
- Pretražite ljekovito bilje po učincima
- Organizirajte svoje interese i budite u toku s istraživanjem vijesti, kliničkim ispitivanjima i patentima
Upišite simptom ili bolest i pročitajte o biljkama koje bi mogle pomoći, unesite travu i pogledajte bolesti i simptome protiv kojih se koristi.
* Svi podaci temelje se na objavljenim znanstvenim istraživanjima
